Indian Pharma Q4 Results Preview: Strong Sales Growth Expected To Boost Profitability In Q4
Sun Pharma is projected to lead in PAT growth at 28% YoY, while Cipla might see a 5% YoY decline, according to Centrum Broking.
As Indian pharmaceuticals commence announcement of fourth quarter earnings, the aggregate picture suggests a 16% year-on-year sales growth for a cohort of key players — Sun Pharmaceutical Industries Ltd., Cipla Ltd., Dr. Reddy's Laboratories Ltd, Torrent Pharma, and JB Chemicals & Pharmaceuticals. This growth could push their combined revenue to a substantial Rs 33,200 crore.
Companies like Dr. Reddy’s, Zydus Lifesciences Ltd., and Lupin Ltd. are likely to post the strongest revenue growth year-on-year. In contrast, companies such as Alkem Labs and IPCA, may see relatively muted performance due to seasonal weakness.
Key Growth Drivers
Growth is expected to be fueled by a 12% expansion in domestic formulations and a more moderate 5% rise in US sales. The depreciation of the Indian rupee against the US Dollar is also expected to provide a tailwind to these figures.
Profitability is anticipated to see a significant uptick, with the aggregate Ebitda margin for these pharma giants projected to expand by approximately 310 basis points to 28%, translating to a 30% YoY growth in Ebita to Rs 9,200 crore, Centrum said. PAT is forecasted to grow by 18% YoY to Rs 6,600 crore.
Sun Pharma is projected to lead in PAT growth at 28% YoY, while Cipla might see a 5% YoY decline, according to the brokerage.
US: Niche Launches, Specialty To Continue Driving Growth
Centrum Broking expects 5% YoY growth in US sales to $1.2 billion for the quarter. The steady growth in US generics is likely to be driven by continued traction in niche launches supported by easing price erosion.
Leading the charge in the US market is Sun Pharma, which is expected to deliver an impressive 12% YoY growth, driven by the continued success of its specialty portfolio, according to Centrum.
Nomura expects the company's large chronic presence, new launches and sales force expansion in the recent past to drive year-on-year growth.
In contrast, Cipla's US sales are anticipated to remain under pressure, declining by 3% YoY, due to ongoing supply-side constraints with Lanreotide, according to the brokerage.
The company's US revenues will be impacted by contribution from gRevlimid, Nomura said. It expects other products to maintain sales quarter-on-quarter.
Dr. Reddy's and Torrent Pharma are both expected to see a more modest 3% growth in their US revenues, Centrum said.
Domestic Formulation Business
DF sales are expected to grow 12% YoY, led by healthy growth in Cardiac/GI/Anti-diabetes which outperformed the IPM during the quarter. However, it is expected to be slightly offset due to subdued growth in Anti-infective/respiratory/Gynaec, according to Centrum Broking
Dr. Reddy's is poised to be the frontrunner among this group, with a remarkable 21% YoY growth in DF sales, largely attributed to the integration of Sanofi's portfolio. Sun Pharma and Torrent Pharma are also expected to showcase strong DF growth at 13% and 11% YoY, respectively, it said.
However, Cipla's growth in the domestic market is likely to be somewhat tempered at 7% YoY, potentially impacted by subdued growth in the respiratory segment, Centrum said. The progress of these companies in the burgeoning GLP-1 product space will be a key area of observation, especially following Eli Lilly's Mounjaro launch in India, alongside the persistent challenge of maintaining volume growth in the branded generics segment, it said.
